BRPI0815748B8 - uso de iota-carragenina em uma quantidade antiviral eficaz - Google Patents

uso de iota-carragenina em uma quantidade antiviral eficaz

Info

Publication number
BRPI0815748B8
BRPI0815748B8 BRPI0815748A BRPI0815748A BRPI0815748B8 BR PI0815748 B8 BRPI0815748 B8 BR PI0815748B8 BR PI0815748 A BRPI0815748 A BR PI0815748A BR PI0815748 A BRPI0815748 A BR PI0815748A BR PI0815748 B8 BRPI0815748 B8 BR PI0815748B8
Authority
BR
Brazil
Prior art keywords
iota
carrageenan
effective antiviral
prophylaxis
infection
Prior art date
Application number
BRPI0815748A
Other languages
English (en)
Inventor
Grassauer Andreas
Prieschl-Grassauer Eva
Original Assignee
Marinomed Biotechnologie Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marinomed Biotechnologie Gmbh filed Critical Marinomed Biotechnologie Gmbh
Publication of BRPI0815748A2 publication Critical patent/BRPI0815748A2/pt
Publication of BRPI0815748B1 publication Critical patent/BRPI0815748B1/pt
Publication of BRPI0815748B8 publication Critical patent/BRPI0815748B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731—Carrageenans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

uso de iota-carragenina em uma quantidade antiviral eficaz a presente invenção fornece o uso de iota e/ou capacarragenina para a produção de uma composição farmacêutica antiviral para a profilaxia ou tratamento de uma doença ou condição patológica causada por ou associada a uma infecção por um vírus respiratório selecionado do grupo consistindo de ortomixovírus, paramixovírus, adenovírus e coronavírus. a presente invenção ainda fornece o uso do fucoidan, em particular fucoidan de alto peso molecular, para a produção de uma composição farmacêutica antiviral para a profilaxia ou tratamento de uma doença ou condição patológica causada por ou associada a uma infecção por um vírus respiratório selecionado do grupo consistindo de ortomixovírus e paramixovírus.
BRPI0815748A 2007-08-24 2008-08-22 uso de iota-carragenina em uma quantidade antiviral eficaz BRPI0815748B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93566807P 2007-08-24 2007-08-24
US60/935668 2007-08-24
PCT/EP2008/006910 WO2009027057A1 (en) 2007-08-24 2008-08-22 Antiviral composition comprising a sulfated polysaccharide

Publications (3)

Publication Number Publication Date
BRPI0815748A2 BRPI0815748A2 (pt) 2015-02-18
BRPI0815748B1 BRPI0815748B1 (pt) 2019-04-24
BRPI0815748B8 true BRPI0815748B8 (pt) 2021-05-25

Family

ID=40198591

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0815748A BRPI0815748B8 (pt) 2007-08-24 2008-08-22 uso de iota-carragenina em uma quantidade antiviral eficaz

Country Status (27)

Country Link
US (2) US20110059919A1 (pt)
EP (1) EP2178533B1 (pt)
JP (1) JP5647518B2 (pt)
KR (1) KR101571571B1 (pt)
CN (1) CN101784272B (pt)
AP (1) AP2630A (pt)
BR (1) BRPI0815748B8 (pt)
CA (1) CA2696009C (pt)
CY (1) CY1113949T1 (pt)
DK (1) DK2178533T3 (pt)
EA (1) EA018138B1 (pt)
ES (1) ES2406684T3 (pt)
HK (1) HK1144558A1 (pt)
HR (1) HRP20130402T1 (pt)
IL (1) IL203444A (pt)
MA (1) MA31748B1 (pt)
MX (1) MX2010001986A (pt)
MY (1) MY153900A (pt)
NO (1) NO20100097L (pt)
NZ (1) NZ583511A (pt)
PL (1) PL2178533T3 (pt)
PT (1) PT2178533E (pt)
SI (1) SI2178533T1 (pt)
TN (1) TN2010000086A1 (pt)
UA (1) UA102673C2 (pt)
WO (1) WO2009027057A1 (pt)
ZA (1) ZA201000951B (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9884024B2 (en) * 2005-12-27 2018-02-06 Hemant N Joshi Physically dispersed, molecularly dissolved and/or chemically bound drug(s) in an empty, hard capsule shell composition
DK2303287T3 (en) * 2008-07-01 2014-02-17 Marinomed Biotechnologie Gmbh Antiallergic marine biopolymers
US8697670B2 (en) * 2009-01-28 2014-04-15 Life Science Nutrition As Compositions and methods of treating viral infections
JP2010248105A (ja) * 2009-04-14 2010-11-04 Bio Plan:Kk ウイルス感染阻害用組成物
US20120189706A1 (en) * 2009-10-06 2012-07-26 Knocean Sciences, Inc. Macrocystis Pyrifera Derived Health and Wellness Products and Methods of Using the Same
JP5902628B2 (ja) * 2009-12-22 2016-04-13 マリノメド バイオテクノロジー ゲゼルシャフト ミット ベシュレンクテル ハフツング 相乗的抗ウイルス組成物及びその使用
JP2011168533A (ja) * 2010-02-18 2011-09-01 Kyosei Seiyaku Kk 抗インフルエンザウイルス剤
SG183289A1 (en) * 2010-02-22 2012-09-27 Marinova Pty Ltd Anti-viral formulations
CN101869110B (zh) * 2010-07-14 2013-03-13 山东圣鹏农药有限公司 一种抗植物病毒病组合物及其应用
WO2012018628A1 (en) 2010-07-26 2012-02-09 Board Of Regents, The University Of Texas System Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine
FR2969926B1 (fr) 2011-01-04 2017-03-10 Elicityl Arabinogalactanes, apiogalacturonanes et heteroglycanes sulfates pour le traitement des maladies causees par les virus influenza
WO2012126777A1 (en) * 2011-03-18 2012-09-27 Marinomed Biotechnologie Gmbh Inhibition of neuraminidase activity
WO2013006795A2 (en) 2011-07-07 2013-01-10 Humanitas International Foundation Antiviral compositions and methods of their use
CN102764266A (zh) * 2012-07-30 2012-11-07 吉林省辉南长龙生化药业股份有限公司 褐藻多糖硫酸酯在制备预防和治疗慢性阻塞性肺病药物中的用途
CN102988409A (zh) * 2012-11-26 2013-03-27 合肥博太医药生物技术发展有限公司 硫酸葡聚糖在制备治疗重症肝炎药物中的应用
RU2686088C2 (ru) * 2013-01-25 2019-04-24 Маринова Пти Лтд Способ обработки экстракта из морских водорослей, экстракт, фармацевтическая композиция, биоматериал, способ лечения, применение экстракта и композиции
US9974850B2 (en) 2013-01-25 2018-05-22 Board Of Regents, The University Of Texas System Immunogenic compositions and uses thereof
CN103301065A (zh) * 2013-06-27 2013-09-18 辽宁亿灵科创生物医药科技有限公司 一种海藻提取物的鼻喷剂及其制备方法
RS59437B1 (sr) 2013-12-03 2019-11-29 Gerolymatos Int S A Jonske vodene kompozicije
HUE044329T2 (hu) 2014-01-22 2019-10-28 Visufarma B V Iota-karragént tartalmazó készítmény vírusos kötõhártya-gyulladás ellen
CN104721221B (zh) * 2015-01-29 2017-08-04 广州暨南生物医药研究开发基地有限公司 琼枝麒麟菜多糖用于制备抗呼吸道病毒药物中的用途
PT3370692T (pt) 2015-07-14 2023-07-18 Marinomed Biotech Ag Composição que elimina a congestão nasal e possui atividade antiviral
US10434119B2 (en) * 2016-01-13 2019-10-08 Gargle Water, Inc. Pharyngeal or buccal cavity rinse and process of use thereof
US20170360815A1 (en) * 2016-02-25 2017-12-21 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
CN105748506B (zh) * 2016-03-03 2018-08-17 青岛海洋生物医药研究院股份有限公司 褐藻酸硫酸酯在制备预防和治疗由人乳头瘤状病毒引起的疾病的药物和保健品中的应用
CN106309470B (zh) * 2016-08-30 2021-05-18 闫滨 一种羊栖菜多糖的应用
WO2018144545A1 (en) 2017-01-31 2018-08-09 Stc.Unm Arginine-rich polypeptide compositions and methods of using same
JP7261367B2 (ja) * 2018-02-14 2023-04-20 江南化工株式会社 抗ウイルス剤及び抗ウイルス組成物
JP6942350B2 (ja) * 2018-04-26 2021-09-29 江南化工株式会社 抗ウイルス剤及び抗ウイルス用組成物
US20230140869A1 (en) * 2018-07-27 2023-05-11 ARC Medical Inc. High-molecular-weight fucans for treating fibrous adhesions and other diseases and conditions
KR101995376B1 (ko) * 2018-08-20 2019-07-02 한미약품 주식회사 카라기난을 유효성분으로 포함하는 항-바이러스 조성물
GB2579600B (en) * 2018-12-05 2023-07-05 Byotrol Plc Anti-viral composition
CN112137953A (zh) * 2019-06-26 2020-12-29 山东百骏生物科技有限公司 一种用于感冒辅助治疗的液体敷料
US11821111B2 (en) 2019-11-15 2023-11-21 Fred Hutchinson Cancer Center Barcoded influenza viruses and deep mutational scanning libraries including the same
WO2021168173A1 (en) * 2020-02-20 2021-08-26 Synkine Therapeutics, Inc. Methods and compositions for treating viral respiratory infections
CA3171013A1 (fr) * 2020-03-09 2021-09-16 Organes Tissus Regeneration Reparation Remplacement Composition pour le traitement de lesions du systeme respiratoire
BR112022018200A2 (pt) 2020-03-12 2022-11-29 Sydney David Cullis Hill Tratamento para infecção por coronavírus e toxicidade de citocinas associadas
WO2021191904A1 (en) * 2020-03-26 2021-09-30 Tree Of Life Pharma Ltd. Methods for preventing and treating viral infection
US20230201249A1 (en) * 2020-04-02 2023-06-29 Linhardt Robert John Compositions incorporating sulfated polysaccharides for inhibiting sars-cov-2
NL2025335B1 (en) 2020-04-10 2021-10-26 Logick Energetics B V Pharmaceutical composition for treatment of corona virus infection
CN111471088B (zh) * 2020-04-21 2021-02-09 北京中科微盾生物科技有限责任公司 一种抑制sars-cov-2感染的多肽、组合物及其用途
WO2021253643A1 (zh) * 2020-06-18 2021-12-23 大连工业大学 硫酸化多糖在抗新型冠状病毒中的应用
CN111686125A (zh) * 2020-06-18 2020-09-22 大连工业大学 卡拉胶在抗新型冠状病毒中的应用
EP3932411A1 (en) 2020-06-30 2022-01-05 GSK Consumer Healthcare SARL Antiviral pharmaceutical composition
EP3932412A1 (en) 2020-06-30 2022-01-05 GSK Consumer Healthcare SARL Antiviral pharmaceutical composition
EP3939597A1 (en) 2020-07-16 2022-01-19 Marinomed Biotech AG Antiviral pharmaceutical composition comprising a carrageenan component
CN114053251A (zh) * 2020-07-29 2022-02-18 苏州融析生物科技有限公司 硫酸化多糖吸入制剂及其在防治新冠病毒相关疾病中的应用
CN112220799A (zh) * 2020-11-02 2021-01-15 江苏泰德医药有限公司 一种抑制病毒的产品及用途
WO2022131282A1 (ja) * 2020-12-15 2022-06-23 正一 中村 海藻類及びその抽出物を含有するせっけん類、消毒剤、殺菌剤及び洗浄剤
WO2022131283A1 (ja) * 2020-12-15 2022-06-23 正一 中村 海藻類及びその抽出物を含有する食品類及び飲料水類
EP4079300A1 (en) 2021-04-22 2022-10-26 Dutch Renewable Energy B.V. Anti-viral composition for administration into nose, mouth or throat
EP4079289A1 (en) 2021-04-22 2022-10-26 Dutch Renewable Energy B.V. Anti-viral composition for administration into nose, mouth or throat
GB202109888D0 (en) 2021-07-08 2021-08-25 Pollinner Ltd Nasal spray
EP4130258A1 (en) 2021-08-02 2023-02-08 Evonik Operations GmbH Microorganisms displaying viral decoy receptors
WO2023031929A1 (en) * 2021-08-31 2023-03-09 Polyrizon Ltd. Mucoadhesive polymers for nasal drug delivery
CN114264530B (zh) * 2021-12-30 2023-05-05 重庆市畜牧科学院 一种基于Avicel的病毒蚀斑测定方法及其应用
CN114395538A (zh) * 2022-01-19 2022-04-26 和元生物技术（上海）股份有限公司 一种促进重组病毒载体向细胞外分泌的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783446A (en) * 1985-11-22 1988-11-08 Neushul Mariculture Incorporated Method for the treatment of AIDS virus and other retroviruses
EP0293826A3 (en) 1987-06-02 1989-05-10 Stichting REGA V.Z.W. Therapeutic and prophylactic application of sulfated polysaccharides against aids
CH680265A5 (en) * 1990-06-25 1992-07-31 Madeleine Luescher Mattli Dr Polyanionic cpds. for treatment of myxo- and para-myxo-virus diseases - effective against e.g. influenza, measles, mumps and distemper and use e.g. a sulphonated polysaccharide
AU1052492A (en) * 1991-01-31 1992-08-06 Farmitalia Carlo Erba S.R.L. Synergistic composition comprising a fibroblast growth factor and a sulfated polylsaccharide, for use as antiviral agent
WO1994015624A1 (en) * 1993-01-08 1994-07-21 The Population Council Use of sulphated polysaccharides for preventing sexually transmitted diseases
US5658893A (en) 1995-03-29 1997-08-19 Abbott Laboratories Method for inhibition of rotavirus infection with carrageenan
AU713527B2 (en) 1996-08-12 1999-12-02 Merck & Co., Inc. Thrombin inhibitors
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
JPH1180003A (ja) * 1997-09-16 1999-03-23 Yakult Honsha Co Ltd 感染症予防・治療剤
DE19961307A1 (de) 1999-12-18 2001-07-12 Krewel Meuselbach Gmbh Medizinprodukt zur Befeuchtung und Reinigung der Nasenschleimhaut
JP2001181188A (ja) * 1999-12-28 2001-07-03 Marine Biotechnol Inst Co Ltd インフルエンザウイルス感染阻害剤
FR2808687B1 (fr) 2000-04-27 2003-12-05 Goemar Lab Sa Medicament contenant des substances polysaccharidiques pour l'activation de l'apoptose
AU2001268884A1 (en) 2000-06-30 2002-01-14 Polydex Pharmaceuticals Limited Cellulose sulfate and other sulfated polysaccharides to prevent and treat papilloma virus infection and other infections
DE10051955A1 (de) * 2000-10-20 2002-05-02 Wella Ag Haarbehandlungsmittel in Form eines festen und formstabilen Gels
JP2003081841A (ja) 2001-06-26 2003-03-19 Kikkoman Corp 抗アレルギー体質強化剤
US20030181416A1 (en) * 2002-01-10 2003-09-25 Comper Wayne D. Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
WO2003093322A2 (en) * 2002-04-30 2003-11-13 The Population Council, Inc. Carrageenan based antimicrobial compositions
US20060078504A1 (en) * 2003-02-26 2006-04-13 Akira Yamamoto Sustanined-release pharmaceutical composition for lung administration
US20050009782A1 (en) 2003-07-09 2005-01-13 Comper Wayne D. Antiviral charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and methods of use thereof
US20080004236A1 (en) 2004-02-06 2008-01-03 Comper Wayne D High Dose, Short Interval Use of Sulfated Polysaccharides for Treatment of Infections
US20080184618A1 (en) * 2005-08-03 2008-08-07 Amcol International Virus-Interacting Layered Phyllosilicates and Methods of Use
US20080241271A1 (en) * 2006-11-08 2008-10-02 Roman Stephen B Foaming anti-adhesion composition

Also Published As

Publication number Publication date
HRP20130402T1 (hr) 2013-06-30
PL2178533T3 (pl) 2013-08-30
EP2178533B1 (en) 2013-03-27
MY153900A (en) 2015-04-15
US20110059919A1 (en) 2011-03-10
AP2010005170A0 (en) 2010-02-28
NZ583511A (en) 2012-02-24
CY1113949T1 (el) 2016-07-27
DK2178533T3 (da) 2013-05-27
KR101571571B1 (ko) 2015-11-24
EA201070299A1 (ru) 2010-08-30
PT2178533E (pt) 2013-06-03
BRPI0815748B1 (pt) 2019-04-24
ES2406684T3 (es) 2013-06-07
MX2010001986A (es) 2010-03-11
KR20100045468A (ko) 2010-05-03
WO2009027057A1 (en) 2009-03-05
US10342820B2 (en) 2019-07-09
AU2008291290A1 (en) 2009-03-05
AP2630A (en) 2013-03-28
EP2178533A1 (en) 2010-04-28
CA2696009A1 (en) 2009-03-05
SI2178533T1 (sl) 2013-07-31
IL203444A (en) 2015-05-31
UA102673C2 (ru) 2013-08-12
ZA201000951B (en) 2011-04-28
JP5647518B2 (ja) 2014-12-24
US20120237572A1 (en) 2012-09-20
BRPI0815748A2 (pt) 2015-02-18
TN2010000086A1 (en) 2011-09-26
CA2696009C (en) 2016-08-02
HK1144558A1 (en) 2011-02-25
CN101784272A (zh) 2010-07-21
JP2011512319A (ja) 2011-04-21
EA018138B1 (ru) 2013-05-30
MA31748B1 (fr) 2010-10-01
CN101784272B (zh) 2014-03-12
NO20100097L (no) 2010-03-24

Similar Documents

Publication Publication Date Title
BRPI0815748B8 (pt) uso de iota-carragenina em uma quantidade antiviral eficaz
BRPI0916235A2 (pt) composto, composição farmacêutica, uso do composto ou da composição, e, método para tratar um paciente infectado com hcv
BR112015014585A2 (pt) composto, composição farmacêutica, e, método de tratamento de um ser humano
BRPI1013984A2 (pt) composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto.
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
BR112012030699A2 (pt) métodos para tratar câncer de bexiga
BRPI1013394A2 (pt) "composto, composição farmacêutica, uso do composto, e, método para tratar um paciente infectado com virus da hepatite c."
BR112015014592A2 (pt) composto, composição farmacêutica, e, método para o tratamento de um humano
BR112015003332A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BRPI0807597A2 (pt) Composição farmacêutica, e, método para tratar infecção por vírus da influenza
BR112015003398A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BRPI1011220A2 (pt) composição farmacêutica, métodos para tratar uma doença ou distúrbio, para administração respiratória de dois ou mais agentes ativos, para administração respiratória de uma combinação de agentes ativos, e, para preparar uma composição adequada.
BR112015006019A2 (pt) composto selecionado, composição farmacêutica, método para tratar uma doença ou distúrbio, uso de um composto, kit para tratar uma condição mediada por pim quinase e invenção.
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112014007532A2 (pt) variantes do fator de crescimento de fibroblastos 21
BR112012002992A2 (pt) composição para cuidado oral, composição, método para inibir formação de biopelícula e/ou degradar uma biopelícula em um paciente, uso de um sesquiterpenóide.
BRPI0819799A2 (pt) Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença
BR112012024260A2 (pt) composições inibidoras virais para uso terapêutico in vivo compreendendo uma combinação de(-)-carvona, (+)-carvona, geraniol e um adicional componente óleo essencial
BR112012032202A2 (pt) formulação de revestimento para a preparação de um revestimento hidrofílico.
BRPI0816814A2 (pt) composto, composição farmacêutica, método para tratar, prevenir ou melhorar uma doença mediada por gsk-3, uso de um composto, e, artigo de fabricação.
BR112012003464A2 (pt) composto, composição farmacêutica, usos de uma composição farmacêutica e de um composto, e, método para tratar uma doença ou um distúrbio."
BR112012015202A2 (pt) "iota - e/ou kappa-carrgenado junto com um inibidor da neuraminidase, método para o tratamento profilático ou terapêutico de um sintoma, condição ou doença, composição farmacêutica,e, kit de partes".
BRPI0923856A2 (pt) composto, composição farmacêutica, uso de um composto, e método para tratar uma doença ou distúrbio.
BR112016024176A2 (pt) composições para tratamento bucal tendo estabilidade aprimorada
ITMI20060158U1 (it) Apparecchiatura per la somministrazione di ossigeno o di aria addizionata da ossigeno,per terapie respiratorie.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/04/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/08/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF